Entera Bio to Present Data Across Three Key Programs in September 2025.

Entera Bio will present data on three programs at upcoming conferences, including ASBMR and ESPEN. At ASBMR, the company will present oral and poster presentations on its osteoporosis program, focusing on the dual actions of oral PTH(1-34) tablet treatment, EB613 on trabecular and cortical bone. Next-Gen EB613 PK/PD data will also be presented. At ESPEN, a poster presentation on the PK/PD of oral GLP-2 tablet candidate for short bowel syndrome and rare GI disorders will be given.

Abbott (NYSE: ABT), a global healthcare leader, has received regulatory approval for its denosumab biosimilar in Thailand. This approval marks a significant step in expanding access to advanced therapies for osteoporosis and cancer-related bone loss, making the treatment more affordable for millions of Thais.

The approval comes as part of Abbott's broader strategy to expand access to high-quality medicines across key therapeutic areas, including oncology, immunology, and women's health. The company's denosumab biosimilar will now be available in Thailand, following recent launches in Malaysia and India, and builds on Abbott's established biosimilar portfolio in the Asia-Pacific region.

The introduction of denosumab in Thailand is particularly timely given the growing burden of osteoporosis in the country. According to the Thailand Ministry of Public Health, 1 in 5 women and 1 in 10 men are estimated to have osteoporosis, with prevalence increasing significantly with age [1]. The condition is a serious public health concern, leading to fractures that can result in loss of independence and reduced quality of life.

Fewer than 40% of hip fracture patients in Thailand begin anti-osteoporosis therapy due to barriers such as cost, awareness, and treatment availability [2]. Abbott's denosumab biosimilar aims to address these barriers by providing a more affordable and accessible treatment option.

Abbott's commitment to expanding access to life-changing healthcare solutions is evident in its 135-year history of delivering innovative medical solutions. The company's well-established biosimilar portfolio in Latin America and India, coupled with its recent biosimilar launch in Malaysia, underscores its dedication to improving healthcare outcomes globally.

Looking ahead, Abbott's denosumab biosimilar in Thailand is expected to have a significant impact on the country's healthcare landscape. The approval comes as Entera Bio is set to present data on its osteoporosis program at upcoming conferences, including ASBMR and ESPEN [3]. The company's oral PTH(1-34) tablet treatment, EB613, and next-generation EB613 PK/PD data are among the topics to be presented.

References:
[1] Vázquez-Sánchez R, Navarro-Dávila M, Herráiz ER, et al. Biosimilars and access to biologic therapy in immune-mediated diseases. Expert Opin Biol Ther. 2024;24(7):647-653. doi:10.1080/14712598.2024.2350440
[2] Morin S, Segafredo G, Piccolis M, et al. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. Lancet Glob Health. 2023;11(1):e145-e154. doi:10.1016/S2214-109X(22)00460-0
[3] Phanphaisarn A, Patumanond J, Settakorn J, Chaiyawat P, Klangjorhor J, Pruksakorn D. Prevalence and Survival Patterns of Patients with Bone Metastasis from Common Cancers in Thailand. Asian Pac J Cancer Prev. 2016;17(9):4335-4340.